Log in

Register Subscribe
The Home of Textile Innovation

ZURICH – Swiss innovator HeiQ has undertaken new tests of its Viroblock NPJO3 antiviral textile treatment, concluding that it’s capable of reducing the virus by 99.99 per cent.

Conducted by the Peter Doherty Institute for Infection and Immunity in Melbourne, HeiQ’s technology – which is a combination of vesicle and silver technologies that work by binding to viral sulfur groups and depleting their membranes – has been found an effective killer of the strain of coronavirus that’s gripped the world.

“The confirmation of antiviral activity of HeiQ Viroblock against SARS-CoV-2 is an important milestone,” said HeiQ CEO, Carlo Centonze. “This data forms part of our ongoing efforts to help provide textiles with greater levels of protection against viruses and contribute to efforts towards mitigation of the global pandemic.”

Why Subscribe?


Weekly e-news bulletin

Latest news direct to your inbox

Interested in advertising?

Simply give us a call

Sales: +44 1977 708488

Or if you prefer email, click on the button below and we'll get back to you asap


Why Subscribe?

Looking beyond the cutting edge of textile innovation allows you to stay well ahead of the competition. That’s exactly what you get through a subscription to T.EVO – which delivers a refreshing new take on the rapid evolution of today’s dynamic textile sector.

Key T.EVO benefits:

You will learn about:

All this from MCL Global – the fastest growing international textile publisher – which can now offer today’s textile industry a unique preview of how today’s industry will look tomorrow.

In print, online and mobile device formats.